ARCALIS
1 known investors
A US-Japan joint venture established in 2021 between Axcelead and US-based Arcturus Therapeutics for domestic mRNA drug/vaccine manufacturing, with sites in Minamisoma (Fukushima) and Kashiwanoha (Chiba).
Investors · 1
Frequently asked questions
- What does ARCALIS do?
- A US-Japan joint venture established in 2021 between Axcelead and US-based Arcturus Therapeutics for domestic mRNA drug/vaccine manufacturing, with sites in Minamisoma (Fukushima) and Kashiwanoha (Chiba).
- Who are ARCALIS's investors?
- ARCALIS's investors include Whiz Partners Inc..